Douglas W. Blayney
Publication Details
-
Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?
Oncologist. 2011; (5): 559-65
The role of continued trastuzumab after progression in women with human epidermal growth factor receptor (HER)-2+ metastatic breast cancer is controversial. Controlled clinical trials that establish a benefit from continued trastuzumab have been difficult to complete.
Help